Research Digest Very Low

Animal-to-Human Translation: What the Numbers Measure

A closer look at animal-to-human translation estimates: which interventions were counted, what each milestone means, and why pooled rates cannot predict a peptide's clinical outcome.

PepCodex Research Team
6 min read
#research #animal-studies #translation #clinical-trials #methodology

A translation rate needs a denominator

An animal result can justify asking a human research question, but it does not establish a human benefit. The widely repeated claim that a fixed percentage of successful mouse studies becomes a treatment has no single, peptide-wide denominator. A rate changes with the interventions selected, the clinical milestone counted, and the time allowed for development.

A 2024 umbrella review assembled 122 reviews covering 54 diseases and 367 therapeutic interventions, including drug and non-drug treatments. Its main progression analysis restricted the denominator to 281 interventions whose first animal experiment was more than ten years earlier. Of that same group, about 50% reached any human study, 40% reached a randomized controlled trial, and 5% received regulatory approval. These are three proportions of the original 281, not successive conditional chances of success. Reaching a human study also says nothing by itself about a favorable result.

These figures do not estimate a named peptide’s chance of approval. The authors selected reviews explicitly concerned with translation, which may overrepresent fields where some clinical translation had already occurred. They did not separately estimate rates for peptides or assess differences by therapy type. Their separate analysis of agreement between animal and human results used 62 therapies with at least five published animal studies; its denominator cannot be substituted for the 281-intervention progression cohort (umbrella review).

Why a promising animal finding can mislead

The question studied in an animal model may differ from the clinical question. A model can use a different population, treatment timing, outcome, or disease course. Van der Worp and colleagues discuss these limits and the role of study design. A systematic review by Perel and colleagues compared animal and clinical treatment effects for six selected interventions; it is evidence that concordance varies in those cases, not a universal failure percentage. The ARRIVE 2.0 reporting guidelines identify details needed to assess an animal experiment, including design, sample size, bias control, and outcomes. Complete reporting makes an assessment possible; it does not prove that a model predicts human outcomes.

BPC-157 shows why the endpoint matters

As of September 2026, published human BPC-157 reports include a two-person intravenous safety pilot and an uncontrolled report in 12 women with interstitial cystitis who received local bladder-area injections. The former measured short-term tolerability and selected laboratory markers after IV infusion; it did not test wound healing. The latter reported symptom responses after a procedure, without a control group; it did not test tendon or muscle repair. Neither report establishes general safety across routes or clinical efficacy for injury recovery. The evidence grade for applying animal findings or pooled translation rates to a specific peptide benefit is very low.

For a step-by-step way to inspect an animal paper, use the animal-study reading checklist.

This article is educational research analysis, not medical advice. Human safety and benefit require indication- and route-specific evaluation.

Sources & Citations

Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.